drugset / Trial / NCT00577837
Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD
RandomizedParallel-groupDouble-blindTreatment
Summary
A Multi-center, Active-controlled (5 mg daily risedronate), Double-blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly for Six Months in Postmenopausal Women with Low Bone Mineral Density.
Timeline
- Start
- 2004-04
- Primary completion
- 2005-06
- Completion
- 2005-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risedronate | Small molecule | 5 mg | Oral |
| Subject | Risedronate | Small molecule | 100 mg | Oral |
| Subject | Risedronate | Small molecule | 150 mg | Oral |
| Subject | Risedronate | Small molecule | 200 mg | Oral |
Indications
No indication recorded.